MIST Stock Analysis: Buy, Sell, or Hold?
MIST - Milestone Pharmaceuticals Inc. Common Shares
$0.70
-0.02 (-3.23%)
▼
5d:
-11.75%
30d:
-24.51%
90d:
-42.06%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 11, 2026
19d
Get Alerted When MIST Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: MIST is down 11.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: MIST is down 11.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: MIST is currently trading at $0.70, which is considered oversold relative to its 30-day fair value range of $0.74 to $0.89.
Technical Outlook: Technically, MIST is in a strong downtrend. The price is currently testing key support at $0.69. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: MIST scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.86 (+742.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MIST is in a strong downtrend. The price is currently testing key support at $0.69. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: MIST scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.86 (+742.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.74 -
$0.89
Company Quality Score
49/100
(HOLD)
Options IV Signal
40th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
56.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 40th percentile)
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 742.4% below Wall St target ($5.86)
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.74 -
$0.89
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.30
(42.7%)
Support & Resistance Levels
Support Level
$0.70
Resistance Level
$0.81
Current Trend
Strong Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.90
Wall Street Target
$5.86
(+742.4%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 22, 2026 8:54 AM ET
Data refreshes hourly during market hours. Next update: 9:54 AM
Data refreshes hourly during market hours. Next update: 9:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MIST showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 60 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 66 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 59 HOLD |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 73 BUY |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 63 BUY |
